Multicenter Prospective Study for the Prediction of Drug-Resistant Pathogens in Hospitalized Patients with Community-Acquired Pneumonia and Healthcare-Associated Pneumonia in Japan (CJLSG 1205)

Multicenter Prospective Study for the Prediction of Drug-Resistant Pathogens in Hospitalized Patients with Community-Acquired Pneumonia and Healthcare-Associated Pneumonia in Japan (CJLSG 1205) - Multicenter Prospective Study for the Prediction of Drug-Resistant Pathogens in CAP and HCAP (CJLSG 1205)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009837

Enrollment

600

Registered

2013-01-24

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-Acquired Pneumonia (CAP) and Healthcare-Associated Pneumonia (HCAP)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Presence of a new infiltrate on a chest radiograph in addition to at least two of the following: 1) new or increased cough or sputum production, 2) pleuritic chest pain, 3) new or increased dyspnea, 4) fever (temperature =>38.0 degrees) or hypothermia (temperature <35.0 degrees), 5) white blood cell count >=10,000 /mm3 or <4,000 /mm3, and 6) new hypoxemia (SpO2 <90% or PaO2 <60 Torr) or deterioration of hypoxemia

Exclusion criteria

Exclusion criteria: 1) Patients with obstructive pneumonia 2) Patients who do not receive initial empirical antibiotic treatment 3) Pneumonia that occurs 48 hours or more after admission 4) Patients who were transferred from other instructions and were already clinically improved 5) Patients who had been previously enrolled in this study

Design outcomes

Primary

Measure	Time frame
Identified pathogens and drug resistance (especially which are not susceptible to beta-lactams, macrolides, and respiratory fluoroquinolones)	—

Secondary

Measure	Time frame
1) Presence or absence of serious illness and the time to develop 2) 30-day mortality and in-hospital mortality 3) Early and late treatment failure	—

Countries

Japan

Contacts

Public ContactDaisuke Kobayashi

Nagoya University Graduate School of Medicine Respiratory Medicine

dkoba@med.nagoya-u.ac.jp052-744-2167

Outcome results